Want to see TSE:MGRO full AI Analyst Report?
MGRO Stock Chart & Stats
C$0.36
-C$0.02(-4.17%)
At close: 4:00 PM EDT
C$0.36
-C$0.02(-4.17%)
Day’s Range― - ―
52-Week RangeC$0.29 - C$0.94
Previous CloseN/A
Volume3.80K
Average Volume (3M)27.52K
Market Cap
C$20.15M
Enterprise ValueC$32.96
Total Cash (Recent Filing)C$419.58K
Total Debt (Recent Filing)C$553.41K
Price to Earnings (P/E)―
Beta0.53
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding62,959,820
10 Day Avg. Volume43,344
30 Day Avg. Volume27,516
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)39.49
Price to Sales (P/S)4.13
P/FCF Ratio-5.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.07
Revenue Forecast (FY)C$25.00M
Bulls Say, Bears Say
Bulls Say
Plant-based Biologics FocusMustGrow's focus on plant-derived biologics positions it within a durable structural trend toward sustainable crop protection. A product portfolio based on mustard seed inputs can offer differentiation vs synthetic chemistries, align with regulatory shifts, and support partner-led commercial rollouts over the medium term.
Moderate LeverageReported debt levels are moderate relative to equity, which reduces immediate solvency pressure and provides more financial flexibility than highly leveraged peers. This manageable leverage improves the company's ability to access incremental financing or restructure funding to support product development and commercialization needs.
Prior Revenue Scale AchievedHaving reached meaningful revenue in prior years demonstrates MustGrow's ability to commercialize products and access distribution channels. That historical scale reduces pure execution risk versus firms without commercial sales and suggests recoverable demand if cost structure and go-to-market execution improve.
Bears Say
Negative Cash GenerationPersistent negative operating and free cash flow represent a structural cash burn that will require external funding or meaningful margin improvement. Continued outflows constrain investment in regulatory approvals, manufacturing scale, and commercial expansion, and raise dilution or debt-refinancing risk over the medium term.
Deeply Negative MarginsVery large negative operating and net margins indicate the current cost structure and pricing cannot sustain profitable operations. Without durable margin recovery from pricing, cost reduction, or higher-margin products, the company will struggle to reach break-even and preserve shareholder equity long term.
Sharp Revenue DeclineA nearly 50% drop in revenue year-over-year signals demand, execution, or channel disruptions. Revenue volatility reduces predictability, impairs fixed cost absorption, and limits ability to scale R&D or commercialization investments, weakening prospects for stable margin and cash-flow recovery.
MustGrow Biologics News
MGRO FAQ
What was MustGrow Biologics’s price range in the past 12 months?
MustGrow Biologics lowest stock price was C$0.29 and its highest was C$0.94 in the past 12 months.
What is MustGrow Biologics’s market cap?
MustGrow Biologics’s market cap is C$20.15M.
When is MustGrow Biologics’s upcoming earnings report date?
MustGrow Biologics’s upcoming earnings report date is Aug 20, 2026 which is in 15 days.
How were MustGrow Biologics’s earnings last quarter?
Currently, no data Available
Is MustGrow Biologics overvalued?
According to Wall Street analysts MustGrow Biologics’s price is currently Overvalued.
Does MustGrow Biologics pay dividends?
MustGrow Biologics does not currently pay dividends.
What is MustGrow Biologics’s EPS estimate?
MustGrow Biologics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MustGrow Biologics have?
MustGrow Biologics has 62,959,820 shares outstanding.
What happened to MustGrow Biologics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of MustGrow Biologics?
Currently, no hedge funds are holding shares in TSE:MGRO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
MustGrow Biologics
MustGrow Biologics Corp. is an agricultural biotechnology enterprise specializing in the creation and commercialization of natural crop protection solutions. These offerings, including biopesticides, biofumigants, and bioherbicides, are uniquely derived from mustard seed. The company provides a pre-planting soil biofumigation technique aimed at combating soil-borne diseases and pests across diverse agricultural commodities, such as fruits and vegetables. Furthermore, MustGrow is actively developing a bioherbicide to manage undesirable plant growth, intended for use in organic farming, home gardens, and broader agricultural sectors. Their portfolio also extends to post-harvest food preservation, applying treatments to inhibit sprouting, disease, and pathogens, thereby enhancing the shelf life of stored products. A significant offering is CannaPM, an active compound effective against both fungal soil ailments and foliar diseases. Established in 2014 and headquartered in Saskatoon, Canada, the company adopted the name MustGrow Biologics Corp. in March 2018, having previously operated as Duport Capital Ltd.
MGRO Earnings Call
Q1 2026
0:00 / 0:00
Technical Analysis
Progressive Planet Solutions Inc
―
Bee Vectoring Technologies International
―
Gensource Potash
―
Verde Agritech
―
Nutrien
―